{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T06:45:55Z","timestamp":1769150755651,"version":"3.49.0"},"reference-count":30,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2016,5,30]],"date-time":"2016-05-30T00:00:00Z","timestamp":1464566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Japanese Circulation Foundation"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet. Med."],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To compare the effects of the basal insulin analogues glargine and detemir on endothelial function and adipocytokine levels in people with Type 2 diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We studied 32 people with Type 2 diabetes whose blood glucose control was unsatisfactory while receiving only oral hypoglycaemic drugs. Participants were randomized to either insulin glargine or detemir for 24 weeks and then crossed over to the other treatment without a washout period. Flow\u2010mediated vasodilatation, adipocytokine levels (plasminogen activator inhibitor\u20101 and leptin\/adiponectin ratio), and fasting ghrelin levels were monitored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HbA<jats:sub>1c<\/jats:sub> levels were significantly decreased by both basal insulin therapies. Body weight was significantly increased by glargine but not by detemir. The proportion of flow\u2010mediated vasodilatation was significantly increased by detemir but not glargine (glargine: from 5.17 \u00b1 0.69 to 5.94 \u00b1 0.83%; detemir: from 4.89 \u00b1 0.78 to 7.92 \u00b1 0.69%). Plasminogen activator inhibitor\u20101 level was significantly decreased by only detemir (glargine: from 16.4 \u00b1 1.8 to 17.3 \u00b1 2.1; detemir: from 19.2 \u00b1 2.8 to 16.0 \u00b1 1.6 ng\/ml). The leptin\/adiponectin ratio was significantly increased only by glargine. Acyl ghrelin level was significantly decreased by glargine but not detemir.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These results suggest that the effect on endothelial function and adipocytokine profiles may differ between glargine and detemir in people with diabetes (Trial registration ID: UMIN000004973).<\/jats:p><\/jats:sec>","DOI":"10.1111\/dme.13151","type":"journal-article","created":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T10:52:43Z","timestamp":1462531963000},"page":"1737-1743","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effect of basal insulin therapy on vascular endothelial function and adipokine profiles in people with Type 2 diabetes"],"prefix":"10.1111","volume":"33","author":[{"given":"H.","family":"Makino","sequence":"first","affiliation":[{"name":"Division of Atherosclerosis and Diabetes National Cerebral and Cardiovascular Centre Suita Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Atherosclerosis and Diabetes National Cerebral and Cardiovascular Centre Suita Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Hosoda","sequence":"additional","affiliation":[{"name":"National Cerebral and Cardiovascular Centre Research Institute Suita Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Koezuka","sequence":"additional","affiliation":[{"name":"Division of Atherosclerosis and Diabetes National Cerebral and Cardiovascular Centre Suita Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tochiya","sequence":"additional","affiliation":[{"name":"Division of Atherosclerosis and Diabetes National Cerebral and Cardiovascular Centre Suita Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Ohata","sequence":"additional","affiliation":[{"name":"Division of Atherosclerosis and Diabetes National Cerebral and Cardiovascular Centre Suita Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Tamanaha","sequence":"additional","affiliation":[{"name":"Division of Atherosclerosis and Diabetes National Cerebral and Cardiovascular Centre Suita Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Division of Preventive Cardiology National Cerebral and Cardiovascular Centre Suita Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Kangawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Kishimoto","sequence":"additional","affiliation":[{"name":"Division of Atherosclerosis and Diabetes National Cerebral and Cardiovascular Centre Suita Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,5,30]]},"reference":[{"key":"e_1_2_9_2_1","first-page":"977","article-title":"The effect of intensive treatment of diabetes on the development and progression of long\u2010term complications in insulin\u2010dependent diabetes mellitus","volume":"329","author":"Diabetes Control and Complications Trial (DCCT) Research Group","year":"2003","journal-title":"N Engl J Med"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-S010"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0006"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-0172"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203858"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.49.6.999"},{"key":"e_1_2_9_9_1","first-page":"2566","article-title":"A meta\u2010analysis of clinical therapeutic effect of insulin glargine and insulin detemir for patients with type 2 diabetes mellitus","volume":"17","author":"Zhuang YG","year":"2013","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)93147-F"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2003.025841"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2129"},{"key":"e_1_2_9_13_1","first-page":"283","article-title":"Two\u2010way crossover comparison of insulin glargine and insulin detemir in basal\u2010bolus therapy using continuous glucose monitoring","volume":"4","author":"Abe S","year":"2011","journal-title":"Diabetes Metab Syndr Obes"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034274"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1758-5996-4-19"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000021127.83364.7D"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2008.05.005"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2011.6"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2007.10.002"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000299"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-015-0208-1"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.10.2488"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2006.12.025"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000227514.50065.2a"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-11-0822"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.22.9959"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/jb\/mvr134"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.01.017"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000183"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2014.09.012"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0880"}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdme.13151","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdme.13151","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.13151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T10:28:31Z","timestamp":1696328911000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.13151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,30]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1111\/dme.13151"],"URL":"https:\/\/doi.org\/10.1111\/dme.13151","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,30]]},"assertion":[{"value":"2016-05-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}